Drug Type Small molecule drug |
Synonyms TU 2218, TU2218 |
Mechanism ALK5 inhibitors(Transforming growth factor beta receptor 1 inhibitors), TGF beta receptor antagonists, VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | US | 10 Mar 2023 | |
Solid tumor | IND Application | KR | - |